MTRIInMed Pharmaceuticals Inc.
Earnings
When InMed Pharmaceuticals Inc. reports, what it reported each quarter, and how the stock took the results.
29 quarters. Sep 30, 2019 to Sep 30, 2026. USD.
Next results · Q2 2027Projected
10-Q due Feb 2 – 16
No earnings release is on file for this company, so the day is the 10-Q’s, projected from its last 8 filings.
- Quarter
- Q2 2027 · Ends about Dec 31, 2026
- 10-Q window
- Feb 2 – 16
Read against Q2 2026
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $820.19K
- Revenue, change from a year earlier: Q2 2026 −26.2%, Q1 2026 −11.4%, Q4 2025 +1.7%, Q3 2025 +7.6%
- Net income
- -$2.03M
- Net income, change from a year earlier: Q1 2027 n/m, Q4 2026 n/m, Q3 2026 n/m, Q2 2026 n/m
- EPS
- -$0.51
- EPS, change from a year earlier: Q1 2027 n/m, Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m
Latest results
- Q1 2027Nov 2, 2026, after the close
- Revenue
- —
- —
- Net income
- -$2.33M
- N/M
- EPS
- -$0.42
- N/M
- Q4 2026Sep 9, 2026, after the close
- Revenue
- —
- —
- Net income
- -$5.84M
- N/M
- EPS
- —
- —
- Q3 2026May 6, 2026, after the close
- Revenue
- —
- —
- Net income
- -$2.97M
- N/M
- EPS
- -$0.73
- N/M
- Q2 2026Feb 11, 2026, after the close
- Revenue
- $820.19K
- −26.2%
- Net income
- -$2.03M
- N/M
- EPS
- -$0.51
- N/M
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2027 | ||||||||||
| Q1 2027 | Sep 30, 2026 | — | Nov 3, 2026 | 34 d | 10-Q | — | — | -$0.42 | — | |
| FY 2026 | ||||||||||
| Q4 2026derived | Jun 30, 2026 | — | Sep 9, 2026 | 71 d | 10-K | — | — | — | — | |
| Q3 2026 | Mar 31, 2026 | — | May 6, 2026 | 36 d | 10-Q | — | — | -$0.73 | — | |
| Q2 2026 | Dec 31, 2025 | — | Feb 11, 2026 | 42 d | 10-Q | $820.19K | −26.2% | -$0.51 | — | |
| Q1 2026 | Sep 30, 2025 | — | Nov 6, 2025 | 37 d | 10-Q | $1.12M | −11.4% | -$0.44 | — | |
| FY 2025 | ||||||||||
| Q4 2025derived | Jun 30, 2025 | — | Sep 23, 2025 | 85 d | 10-K | $1.30M | +1.7% | — | — | |
| Q3 2025 | Mar 31, 2025 | — | May 12, 2025 | 42 d | 10-Q | $1.26M | +7.6% | -$1.94 | — | |
| Q2 2025 | Dec 31, 2024 | — | Feb 12, 2025 | 43 d | 10-Q | $1.11M | −10.4% | -$3.64 | — | |
| Q1 2025 | Sep 30, 2024 | — | Nov 14, 2024 | 45 d | 10-Q | $1.26M | +40.2% | -$2.71 | — | |
| FY 2024 | ||||||||||
| Q4 2024derived | Jun 30, 2024 | — | Sep 30, 2024 | 92 d | 10-K | $1.28M | −44.5% | — | — | |
| Q3 2024 | Mar 31, 2024 | — | May 14, 2024 | 44 d | 10-Q | $1.17M | +13.4% | -$3.58 | — | |
| Q2 2024 | Dec 31, 2023 | — | Feb 13, 2024 | 44 d | 10-Q | $1.24M | +164.0% | -$3.71 | — | |
| Q1 2024 | Sep 30, 2023 | — | Nov 14, 2023 | 45 d | 10-Q | $901.86K | +181.1% | -$15.24 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Jun 30, 2023 | — | Sep 29, 2023 | 91 d | 10-K | $2.31M | — | — | — | |
| Q3 2023 | Mar 31, 2023 | — | May 15, 2023 | 45 d | 10-Q | $1.03M | +234.0% | -$0.60 | — | |
| Q2 2023 | Dec 31, 2022 | — | Feb 17, 2023 | 48 d | 10-Q | $469.78K | +77.2% | -$0.91 | — | |
| Q1 2023 | Sep 30, 2022 | — | Nov 14, 2022 | 45 d | 10-Q | $320.79K | — | -$4.06 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Jun 30, 2022 | — | Sep 23, 2022 | 85 d | 10-K | — | — | — | — | |
| Q3 2022 | Mar 31, 2022 | — | May 13, 2022 | 43 d | 10-Q | $309.59K | −29.2% | -$6.14 | — | |
| Q2 2022 | Dec 31, 2021 | — | Feb 14, 2022 | 45 d | 10-Q | $265.09K | −4.2% | -$7.73 | — | |
| Q1 2022 | Sep 30, 2021 | — | Nov 10, 2021 | 41 d | 10-Q | — | — | -$6.17 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Jun 30, 2021 | — | Sep 24, 2021 | 86 d | 10-K | — | — | — | — | |
| Q3 2021 | Mar 31, 2021 | — | May 13, 2021 | 43 d | 10-Q | $437.31K | — | -$0.41 | — | |
| Q2 2021 | Dec 31, 2020 | — | Feb 11, 2021 | 42 d | 10-Q | $276.79K | — | -$0.37 | — | |
| Q1 2021 | Sep 30, 2020 | Nov 13, 2020 · market hours | Dec 17, 2020 | 78 d | 10-Q | — | — | -$0.31 | — | |
| FY 2020 | ||||||||||
| Q4 2020derived | Jun 30, 2020 | — | — | — | — | — | — | — | — | |
| Q3 2020 | Mar 31, 2020 | — | — | — | — | — | — | -$0.39 | — | |
| Q2 2020 | Dec 31, 2019 | — | — | — | — | — | — | -$0.48 | — | |
| Q1 2020 | Sep 30, 2019 | — | — | — | — | — | — | -$0.54 | — | |
Earlier years, FY 2020 to FY 2024The latest three years
Source filings
Provenance
ProvenanceData status and checks
InMed Pharmaceuticals Inc. · CIK 1728328 · Engraved from SEC EDGAR